RWS shares spiked 12.4% to 108.3p after the language-services company announced a binding agreement to acquire Acogroup, the Paris-based owner of Acolad. Acolad operates with roughly 1,200 employees across 22 countries in Europe and North America and maintains a network of more than 10,000 linguists and subject-matter experts.
The transaction carries an enterprise value of 22.4 million, equivalent to about two times Acolad 's adjusted EBITDA. Total consideration for the deal is 0.2 million, of which 7.8 million will be held as cash acquired at completion, and no third-party debt will transfer to RWS.
RWS has highlighted the strategic logic of integrating its AI platforms - including Language Weaver Pro, its Cultural Intelligence Layer, and next-generation Transform solutions - into Acolad 's existing European client roster. About half of Acolad 's clients operate in regulated sectors such as medical devices and life sciences, which the company identified as a focus for cross-selling advanced AI-enabled language and content services.
Investors also noted that the acquisition brings interpreting capabilities and a deeper presence among large French corporations - notably those in the CAC 40 - which RWS said would broaden its addressable market. Completion of the transaction is anticipated by 31 March 2027, subject to obtaining the necessary French regulatory clearances.
Today's market reaction was supported by recent operational momentum at RWS. The company's most recent half-year results reported revenue rising 5%, adjusted EBITDA up 20%, and adjusted profit before tax increasing by 33%. The firm also disclosed that AI-related services now represent roughly one third of total revenue.
Analysts were already constructive heading into the announcement. Consensus ratings placed the stock at Strong Buy, with an average 12-month price target of 152p - notably above recent trading levels. Broader equity markets were modestly positive on the day, though market-wide moves were viewed as secondary to company-specific news.
Taken together, the Acolad transaction was interpreted by investors as tangible evidence that RWS is pursuing a technology-led growth strategy via targeted bolt-on acquisitions, following its earlier completion of the Obviously Group acquisition this year. Market participants cited the deal 's attractive pricing, the potential to monetise a large European client base, and an already-positive analyst community as factors that set the stage for the sharp re-rating of shares observed today.
Key points
- RWS agreed to buy Acogroup, parent of Acolad, for an enterprise value of 022.4m and total consideration of 0.2m.
- Deal provides cross-sell opportunities for RWS's AI platforms into Acolad's European client base, around half of which are in regulated industries such as medical devices and life sciences.
- RWS reported improving fundamentals in its latest half-year results and entered the deal with analysts already recommending Strong Buy with an average 12-month target of 152p.
Risks and uncertainties
- Regulatory approval in France is required for completion; the deal is subject to French regulatory clearances and is expected to close by 31 March 2027.
- Realising the intended cross-sell benefits depends on effective integration of AI platforms into Acolad's client relationships and operations.
- Execution risks related to bolt-on acquisitions and the ability to monetise the expanded client base may affect the anticipated strategic benefits.